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Abstract
Post-traumatic haemorrhage is the leading cause of death in
trauma patients. The development of coagulopathy substantially
contributes to bleeding severity and to the ensuing unfavourable
outcome. Trauma-induced coagulopathy (TIC) can be seen in 10-
25% of patients with major trauma, and its early and appropriate
therapeutic management leads to considerable reduction of mortal-
ity risk. Due to the extreme complexity of TIC pathophysiology,
the limitations of conventional coagulation tests (CCTs) have
become evident in recent years. Unlike these routine tests, point of
care viscoelastic tests (VET) such as thromboelastogram (TEG) or
rotational thromboelastography (ROTEM) provide valuable clini-
cal information by real time assessment of changes in viscoelastic
properties of blood throughout clot formation. This review was
aimed to collect and discuss available evidence on goal-directed
hemostatic resuscitation, based on TEG or ROTEM data. We
included studies with patients aged 18 years or older, major trau-
ma, and needing massive transfusions. Overall, 6 studies totalling
1533 patients were finally included. A total number of 288 patients
died, 98 of whom in the TEG- or ROTEM-guided cohorts (i.e.,
intervention groups). A 36% reduction of death was observed in
the intervention groups (relative risk, 0.641; 95% CI 0.517-0.795;
P<0.001). Our results show that VET-guided management is effec-
tive to reduce mortality compared to conventional management
with CCTs. Except for mortality, all others endpoints were hetero-
geneous across the studies. This emphasize the need of scheduling
new and well-designed trials, aimed to better define the optimal
strategy for TIC management.
Introduction
Physical injuries, especially those attributable to road traffic
accidents, are a leading cause of death and morbidity worldwide,
accounting for up to 1.5 million annual deaths and thus represent-
ing the most common cause of death for subjects aged between 15
to 49 years.1-3 The 2002-2004 mortality data from National
Statistical Authorities in the 272 European Union regions attests
that 6.9% and 3.5% of all deaths in men and women, respectively,
were caused by injuries. Nearly 22% of all these fatal injuries
could be attributable to transport accidents, especially road traffic
crashes, whilst 19.4% of all injury deaths were actually due to acci-
dental falls.4
Post-traumatic haemorrhage is the leading cause of death in
trauma patients. The development of coagulopathy consistently
contributes to the bleeding severity and to the ensuing
unfavourable outcomes.5 Trauma-induced coagulopathy (TIC) can
be seen in 10-25% of patients with major trauma, and its early and
appropriate management leads to a substantial reduction of mortal-
ity risk.6-9 The aetiology of TIC has been a matter of speculation for
long. The rather simplistic theory, widely acknowledged as the
lethal triad theory (i.e., including hypothermia, hemodilution and
acidosis), seems insufficient to fully explain the large array of
pathophysiologic mechanisms underlying the early and late coag-
ulopathy that often develop after major trauma.9,10 Several factors,
such as hypofibrinogenemia, release of prothrombotic substances
(namely tissue factor) and activation of blood coagulation, con-
sumption or dilution of clotting factors, platelet dysfunction, dis-
seminated intravascular coagulation (DIC) and hyperfibrinolysis
have all been implicated.11-15 Nevertheless, TIC is currently regard-
ed as a multifactorial condition, which results from a combination
of tissue injury and hypo-perfusion.9,11 Shock is seemingly the
main trigger, whilst the occurrence of tissue damage is a pre-req-
uisite for the onset of TIC. After development and worsening of
shock, fluid resuscitation is a mainstay of management, but it fur-
ther promotes hemodilution, which in turn exacerbates the pre-
existing coagulation abnormalities. When bleeding cannot be effi-
ciently arrested or controlled, hypothermia and acidosis also devel-
op, thus further worsening the coagulopathy, and possibly trigger-
ing DIC, the presence of which characterizes the worst form of
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TIC. A vicious circle, often leading to patient death, is then estab-
lished.16 Tissue inflammation has also been studied as a contribut-
ing factor, but evidence on its real contribution to the pathogenesis
of TIC remains elusive.13,17,18
TIC usually develops very early, within few minutes after trau-
ma, and this would rule out that the lethal triade should be regard-
ed as a pivotal factor, at least in the earliest phases. Floccard et al.
collected blood samples from 45 major trauma patients on the
scene, followed by further sampling in the Emergency Department
(ED). The authors could identify the presence of coagulation
abnormalities in 56% of patients within 25 min from the event, and
in as many as 60% of them upon ED admission, which would lead
to conceive that TIC may not always be a consequence of fluid
resuscitation.19
TIC is also an independent risk factor for early death, need of
blood transfusion, thrombosis and sepsis.9,20
Due to the extreme complexity of TIC pathophysiology, the
limitations of conventional coagulation tests (CCTs), such as pro-
thrombin time/international normalized ratio, activated partial
thromboplastin time, platelet counts and fibrinogen, have become
evident in recent years.21 Unlike these routine laboratory tests,
point of care viscoelastic tests (VET) such as thromboelastogram
(TEG) or rotational thromboelastography (ROTEM) can provide
valuable clinical information by real time assessment of changes in
viscoelastic properties of blood throughout clot formation, thus
overcoming the many inherent limitations of CCTs (i.e., they only
provide information on limited aspects of primary or secondary
hemostasis and do not actually mirror clot stability and fibrinoly-
sis).22,23 Since blood coagulation is assessed at the bedside rather
than with central lab testing, the turnaround time is also consistent-
ly shortened using VET. Moreover, TEG and ROTEM are whole
blood-based tests, so that they allow investigating the intricate
interplay between clotting factors and blood cells, especially
platelets (i.e., between primary and secondary hemostasis). The
results are generated with a graphic layout and in real time,
throughout clot development, at body temperature.22,24 Based on
this evidence, it has recently been suggested that VETs may
replace CCTs for guiding blood component transfusion in trauma
patients.25 Beside trauma-care, these tests are now frequently used
in many cardiothoracic surgery or organ transplant centres, where
they allow a substantial saving of blood derivatives, and enable
achieving better clinical outcomes.26
Three main strategies are currently used for managing severe
bleeding in trauma patients, i.e., i) the hemostatic resuscitation; ii)
the goal-directed hemostatic resuscitation approach; iii) the
Copenhagen Concept.
Hemostatic resuscitation encompasses an early transfusion
strategy based on a fixed erythrocytes:plasma:platelets ratio of
1:1:1, aimed to avoid the so-called dilutional coagulopathy.6 The
Prospective, Observational, Multicenter, Major Trauma
Transfusion (PROMMTT) study showed a reduction in mortality,
as well as an early achievement of higher plasma and platelet ratios
in patients receiving transfusions of at least 3 units of blood prod-
ucts during the first 24 hours after admission.27 The same Authors,
arguing whether or not the 1:1:1 ratio is the optimal resuscitation
strategy for all seriously injured patients, have hence planned the
only randomized prospective study available so far to test this
hypothesis. In the PROPPR Trial, the 1:1:1 and 1:1:2 (plasma,
platelets, red blood cells) ratios were compared. Notably, no signif-
icant difference was observed for 24 hours mortality rate, whilst
exsanguination (i.e., the predominant cause of death within the
first 24 hours) was found to be significantly decreased in the 1:1:1
group. A higher number of patients in the 1:1:1 group also
achieved effective hemostasis than in the 1:1:2 group. Albeit the
1:1:1 group received more plasma and similar amounts of red
blood cells units during the first 24 hours, no difference between
the two groups could be observed for acute respiratory distress
syndrome, multiple organ failure, venous thromboembolism, sep-
sis and transfusion-related complications.28,29
The goal-directed hemostatic resuscitation strategy entails the
early goal concept of selective administrating clotting factors,
associated with the damage control strategy, aimed to avoid colloid
administration during resuscitation. This approach is based on the
use of VETs for monitoring the evolution of TIC combined with
administration of specific clotting factors (i.e., fibrinogen, pro-
thrombin complex, factor VII or factor XIII) when appropriate and
needed.30-33
The Copenhagen Concept lies in between the two formerly
cited strategies, by proposing early hemostatic resuscitation with
fixed erythrocytes:plasma:platelets ratio of 1:1:1, then followed by
a more thoughtful administration of clotting factors, mostly guided
by results obtained using either TEG or ROTEM.34
The European Guidelines suggest an initial administration of
fresh frozen plasma (FFP) (Grade 1B recommendation) or fibrino-
gen (Grade 1C recommendation) in patients with massive bleed-
ing. When further FFP needs to be administered, the guidelines
suggest an optimal FFP: red blood cell ratio of at least 1:2 (Grade
2C recommendation).35
Methods of research
Based on the aforementioned preliminary data, a number of
studies have been published on VETs-guided management of
severe bleeding in trauma patients. Therefore, the aim of this study
is to collect and discuss the available evidence on goal-directed
hemostatic resuscitation regarding the clinical management of
severe bleeding in trauma patients.
An electronic search was conducted in Medline (PubMed
interface) using the keywords “thromboelastography”, “TEG”,
“thromboelastometry”, “ROTEM” and “trauma patients”, limited
to the past 30 years and with no language restriction. Overall, 213
studies could be identified, 43 fulfilled the inclusion criteria and 6
could then be included in meta-analysis. A total number of 37 stud-
ies were excluded due to inappropriate patient population or study
design (i.e., paediatric or surgical patients, comparison between
TEG and rapid-TEG, review articles). Our analysis only included
studies with patients aged 18 years or older, major trauma, and
needing massive transfusions. After application of these inclusion
and exclusion criteria, 6 studies, totalling 1533 patients, could be
included in our study. With the only exception of the randomized
controlled trial published by Gonzalez et al.,30 the remaining stud-
ies were cross-sectional and retrospective (i.e., groups convention-
ally managed versus groups treated with goal-directed hemostatic
resuscitation). The main endpoints included mortality, need for
transfusions, hospital length of stay (LOS) and intensive care unit
(ICU) LOS. The characteristics of the 6 studies are summarized in
Table 1.30-33,36,37
A random-effects model (DerSimonia-Laird method) or a
fixed-effects model (Mantel-Haenszel method) were then applied
when significant (I2≥50% and P<0.1) or insignificant heterogene-
ity could be calculated. Heterogeneity was tested by estimating the
proportion of between-study inconsistencies due to actual differ-
ences among studies rather than differences due to random error or
chance, using the I2 statistic.











The main characteristics of the studies included in this analysis
are shown in Table 1. The injury severity score differences of
patients included in the 6 studies did not reach statistical signifi-
cance (Figure 1; 95% CI -0.157-0.090; P=0.597).
Overall, 288 patients died in the 6 studies, 98 of whom in the
intervention (i.e., VET-guided management) groups. A significant
reduction of death was found in the intervention groups (relative
risk, 0.641; 95% confidence interval [95% CI], 95% CI 0.517-
0.795; P<0.001) (Figure 2). 
Regarding the specific studies, Yin et al. reported a non-signif-
icant reduction in transfusion needs (red blood cell, 5 vs 6.5 units,
P=0.22; platelets 0 vs 0 units, P=0.15; FFP, 5.7 vs 6.1 units,
P=0.54). A trend toward a greater LOS was found in the interven-
tional group (ICU LOS 12.2±11.8 vs 8.1±5.5 days, P=0.28;
Hospital LOS 15.6±12.7 vs 11.3±6.2 days, P=0.10).33
Schochl et al. failed to find a significant difference in ICU
LOS (14.5 vs 14.0 days, P=0.95), whilst Hospital LOS was signif-
icantly decreased in the intervention group (23 vs 32 days,
P<0.005). Patients in control group received a median of 6 FFP
Units, whilst those in the intervention group received a median of
6 g of fibrinogen concentrate and 1200 IU of prothrombin com-
plex. Blood transfusion could be avoided in 29% of patients in the
intervention group compared to only 3% in the control group
(P<0.001). Platelet transfusion was avoided in 91% of patients in
the intervention group compared to 56% in the control group
(P<0.001).31
Nardi et al. reported a significant difference between groups
only for FFP use (4.21±4.61 vs 8.97±9.47 U., P<0.05). No other
significant difference was found, albeit a trend toward reduced
transfusions need was found (red blood cells, 6.5±4.8 vs 8.09±6.7
U., P>0.05; platelets, 2.68±4.75 vs 4.18±5.9 U., P>0.05).36
                             Review
Table 1. Characteristics and results of the analyzed studies.
Study               Method              Controls/    Test             ISS          Mortality              RBC                        PLT                           FFP                      ICU LOS
                                                Intervention             (mean±SD)       (n)       (units; mean±SD) (units; mean±SD)   (unit; mean±SD)  (days; mean±SD)
                                                       (n)                                                                                                                                                                              
Yin et al.,               Retrospective                 31              TEG             14.3±5.7                   2                       6.5 (4-14)                        0 (0-10)                          6.1 (4-10.7)                8.1±5.5 11.3±6.2
201433                                                                29                                     16.2±8                    3                         median                           median                              median
                                                                                                                                                                              5 (3-13)                           0 (0-0)                           5.7 (3.4-10)             12.2±11.8 15.6±12.7
Schochl et al.,      Retrospective                601          ROTEM         35.2±12.5                60                        97% pts                          44% pts                                                                         14  32
201131                                                                80                                    35±10.5                   6                         71% pts                           9% pts                                                                         14.5  23
Nardi et al.,          Retrospective                130          ROTEM              32.5                      26                       8.09±6.7                         4.18±5.9                            8.97±9.47
201536                                                                96                                         33                       13                        6.5±4.8                         2.68±4.75                           4.21±4.61                                 
Tapia et al.,          Retrospective                124             TEG               24±15                   67
201332                                                               165                                    23±14                   55                                                                                                                                                             
Gonzalez et al.,   Randomized                   55              TEG                   33                       20                       11 (6-16)                          1 (0-2)                               6 (4-9)
201630                     prospective                     56                                       29.5                      11                        median                           median                              median                                   
                                                                                                                                                                     9.5 (5-16)                1 (0-2)                             5 (3-9)
Wang et al.,           Retrospective                 80              TEG                   32                       15                          9±10                             2.9±4.8                                  5±6                      13.6±14 8.8±10.6
201737                                                                86                                         28                       10                           4±7                              0.4±1.5                                  1±5                          19±16 14±12
ISS, Injury Severity Score; RBC, red blood cells; PLT, platelets; FFP, fresh frozen plasma; ICU, intensive care unit; LOS, length of stay; pts, patients; TEG, thromboelastogram; ROTEM, thromboelastography.
Figure 1. Forest plot of injury severity score. SMD, standard mean difference; CI, confidence interval.
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Unlike the previous studies, Tapia et al. separated blunt from
penetrating trauma patients, concluding that TEG-guided resusci-
tation was similar to standardized massive transfusion protocols in
blunt trauma patients receiving 6 units or more of red blood cells
and in penetrating trauma patients receiving 10 units or more of red
blood cells. Nevertheless, higher mortality was observed with mas-
sive transfusion protocols in penetrating trauma patients receiving
10 units or more of red blood cells, thus emphasizing the impor-
tance of continuous TEG-guided therapy. This would lead to con-
clude that a 1:1:1 strategy may not be adequate in all patients.32
In the only prospective randomized trial published by
Gonzalez et al. (including a total number of 111 patients), patient
survival in the TEG group was found to be significantly higher
than in the CCTs group. More specifically, 20 deaths could be
recorded in the CCTs group (36.4%) compared to 11 in the TEG
group (19.6%; P=0.049), respectively. Most deaths occurred with-
in the first 6 hours (21.8% in CCTs group vs 7.1% in TEG group;
P=0.032). Although CCTs patients needed a similar number of red
blood cell units as TEG patients, patients in the CCTs group
received more FFP and platelets units in the first 2 hours of resus-
citation.30
In the last study, Wang et al. 37 reported a significant difference
between the intervention and control groups for all the endpoints
studied (red blood cells, 4±7 vs 9±10 units, P<0.01; platelets,
0.4±1.5 vs 2.9±4.8 units, P<0.01; FFP, 1±5 vs 5±6 units, P<0.01;
ICU LOS 8.8±10.6 vs 13.6±14 days, P<0.05; hospital LOS 14±12
vs 19±1 days, P< 0.005).
Discussion and Conclusions
The results of this analysis show that up to 36% lower mortal-
ity can be reached in major trauma patients whose treatment is
guided by VET than in these conservatively managed with CCTs.
The intervention group (i.e., VET-guided treatment) included
patients managed according to TEG or ROTEM data, following
the so-called goal-directed hemostatic resuscitation. This approach
was also associated with a broadly variable (i.e., due to the hetero-
geneity of the studies) lower use of blood products, thus achieving
the goal of optimizing administration of these therapeutic products,
which are not completely free from side effects. Beside viral infec-
tions, the use of FFP is associated with a higher risk of acute lung
injury (transfusion related acute lung injury or acute respiratory
distress syndrome), fluid overload, immune system depression.
Little dose of FFP is not efficient to completely correct TIC, whilst
larger amounts generate a dilutional effect of blood cells, which
then needs further transfusion of packed red blood cells.21,38
The effectiveness of VETs guidance in resuscitation has been
recognized for decades in the area of cardiothoracic surgery and
organ transplantation. Regarding massive trauma, only retrospec-
tive observational studies have been published so far, except for
that of Gonzalez et al.30
There is a rather long history on VETs use on clinical practice,
which commenced early after the pioneering work of Hellmut
Hartert, in 1948, who described the hemostatic potential of whole
blood samples using TEG.39 The first clinical use of TEG to guide
blood component transfusion in trauma populations can be brought
back to the Vietnam War, in the late 1950s.40
VETs display several advantages compared to CCTs, but are
plagued by some limitations. These tests, for example, have het-
erogeneous sensitivity for diagnosing hyperfibrinolysis.41,42
Moreover, they are carried out at standard human body tempera-
ture (i.e., 37°C), so that hypothermic patients should be
rewarmed.43,44 In the hemorragic patient, low hematocrit may
worsen bleeding in vivo, but is effective to improve some VETs
variables in vitro. VETs results, therefore, should be interpreted
according to severity of anemia, hemodilution and some other clin-
ical parameters.45,46
Notwithstanding these limitations, our study attempted to pro-
vide some reliable evidence on the practical use of VETs for guid-
ing resuscitation in trauma patients. Except for mortality, for which
a significant trend toward reduction could be clearly demonstrated,
the data of all the others endpoints were largely heterogeneous
across the various studies. This emphasize the need of planning
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new and well-designed trials, aimed to better define the optimal
strategy for TIC management.
In conclusion, the use of VETs for managing massive trauma
patients may be effective for optimizing the administration of
blood products and for lowering mortality. However, before VET-
guided therapeutic management of TIC patients can be widely rec-
ommended, their limitations need to be acknowledged and
addressed. These typically include quality assurance and availabil-
ity of trained personnel capable to perform and interpret the test in
a typical extra-laboratory environment (e.g., the ICU). However,
the use of VET-guided administration of blood components and
hemostatic agents for damage control resuscitation is now becom-
ing a more widely accepted strategy for trauma patients. Specific
training will be needed for using these tests by emergency physi-
cians, trauma surgeons, anesthesiologists and other trauma-related
staff. With only one exception, randomized controlled trials on the
use of VETs are substantially lacking in TIC, which may be seen
as a serious threat for widespread use of this promising tests in rou-
tine management of massive trauma patients.
References
1. Lozano R, Naghavi M, Foreman K, et al. Global and regional
mortality from 235 causes of death for 20 age groups in 1990
and 2010: a systematic analysis for the Global Burden of
Disease Study 2010. Lancet 2012;380:2095-128.
2. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health,
1990-2010: burden of diseases, injuries, and risk factors.
JAMA 2013;310:591-608.
3. Rhee P, Joseph B, Pandit V, et al. Increasing trauma deaths in
the United States. Ann Surg 2014;260:13-21.
4. European Communities. Health statistics – atlas on mortality
in the European Union. Available from: http://epp.eurostat.
ec.europa.eu/cache/ITY_OFFPUB/KS-30-08-357/EN/KS-30-
08-357-EN.PDF
5. Tieu BH, Holcomb JB, Schreiber MA. Coagulopathy: its
pathophysiology and treatment in the injured patient. World J
Surg 2007;31:1055-64.
6. Cohen MJ. Towards hemostatic resuscitation: the changing
understanding of acute traumatic biology, massive bleeding
and damage control resuscitation. Surg Clin North Am
2012;92:877-91.
7. Norton R, Kobusingye O. Injuries. N Engl J Med 2013;368:
1723-30.
8. MacKenzie EJ, Rivara FP, Jurkovich GJ, et al. A national eval-
uation of the effect of trauma-center care on mortality. N Engl
J Med 2006;354:366-78.
9. Cannon JW. Hemorrhagic Shock. N Engl J Med
2018;378:370-9.
10. Theusinger OM, Bauling W, Levy JH. Coagulation in trauma.
Trends Anaesth Crit Care 2015;5:23-7.
11. Frith D, Goslings J, Gaarder C, et al. Definition and drivers of
acute traumatic coagulopathy: clinical and experimental inves-
tigations J Thromb Haemost 2010;8:1919-25.
12. Maegele M, Lefering R, Yucel N, et al. Early coagulopathy in
multiple injury: an analysis from the german trauma registry
on 8724 patients. Injury 2007;38:298-304.
13. Brohi K, Cohen M, Ganter M, et al. Acute traumatic coagu-
lopathy: initiated by hypoperfusion. Modulated through the
protein C pathway? Ann Surg 2007;245:812-8.
14. Solomon C, Traintinger S, Ziegler B, et al. Platelet function
following trauma: a multiple electrode aggregometry study.
Thromb Haemost 2011;106:322-30.
15. Cap A, Hunt B. The pathogenesis of traumatic coagulopathy.
Anaesthesia 2015;70:E32-4.
16. Lippi G, Cervellin G. Disseminated intravascular coagulation
in trauma injuries. Semin Thromb Hemost 2010;36:378-87.
17. Hess JR, Brohi K, Dutton R, et al. The coagulopathy of trauma:
a review of mechanisms. J Trauma 2008;65:748-54.
18. Wafaisade A, Wutzler S, Lefering R, et al. Drivers of acute
coagulopathy after severe trauma: a multivariate analysis of
1987 patients. Emerg Med J 2010;27:934-9.
19. Floccard B, Rugeri L, Faure A, et al. Early coagulopathy in
trauma patients: an on-scene and hospital admission study.
Injury 2012;43:26-32.
20. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of
trauma: mechanism, identification and effect. Curr Opinion
Crit Care 2007;13:680-5.
21. Walsh M, Fritz S, Hake D, et al. Targeted
Thromboelastographic (TEG) blood component and pharma-
cologic hemostatic therapy in traumatic and acquired coagu-
lopathy. Current Drug Targets 2016;17:954-70.
22. Ganter MT, Hofer CK. Coagulation monitoring: current tech-
niques and clinical use of viscoelastic point-of-care coagula-
tion devices. Anesth Analg 2008;106:1366-75.
23. Da Luz LT, Nascimento B, Shankarakutty AK, et al. Effect of
thromboelastography (TEG) and rotational thromboelastome-
try (ROTEM) on diagnosis of coagulopathy, transfusion guid-
ance and mortality in trauma: descriptive systematic review.
Crit Care 2014;18:518.
24. Cotton BA, Faz G, Hatch QM, et al. Rapid thromboelastogra-
phy delivers real-time results taht predict transfusion within 1
hour of admission. J Trauma 2011;71:407-7.
25. Holcomb J, Minei K, Scerbo M, et al. Admission rapid
thrombelastography can replace conventional coagulation tests
in the emergency department: experience with 1974 consecu-
tive trauma patients. Ann Surg 2012;256:476-86.
26. Schochl H, Voelckel W, Grassetto A, et al. Practical application
of point-of-care coagulation testing to guide treatment deci-
sions in trauma. J Trauma Acute Care Surg 2013;6:1587-98.
27. Holcomb JB, del Junco DJ, Fox EE, et al. The Prospective,
Observational, Multicenter, Major Trauma Transfusion
(PROMMTT) study comparative effectiveness of a time-vary-
ing treatment with competing risks. JAMA Surg
2013;148:127-36.
28. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plas-
ma, platelets, and red blood cells in 1:1:1 vs a 1:1:2 ratio and
mortality in patients with severe trauma: the PROPPR random-
ized clinical trial. JAMA 2015;313:471-82.
29. Moore EE, Moore HB, Chapman MP, et al. Goal-directed
hemostatic resuscitation for trauma induced coagulopathy:
maintaining homeostasis. J Trauma Acute Care Surg
2018;84:S35-40.
30. Gonzalez E, Moore EE, Moore HB, et al. Goal-directed hemo-
static resuscitation of trauma-induced coagulopathy: a prag-
matic randomized clinical trial comparing a viscoelastic assay
to conventional coagulation assays. Ann Surg 2016;263:1051-
9.
31. Schochl H, Nienaber U, Maegele M, et al. Transfusion in trau-
ma: thromboelastometry-guided coagulation factor concen-
trate-based therapy versus standard fresh frozen plasma-based
therapy. Crit Care 2011;15:R83.
32. Tapia NM, Chang A, Norman M, et al. TEG-guided resuscita-
tion is superior to standardized MTP resuscitation in massively










                                    [Emergency Care Journal 2018; 14:7569]                                                    [page 101]
transfused penetrating trauma patients. J Trauma Acute Care
Surg 2013;74:378-86.
33. Yin J, Zhao Z, Li Y, et al. Goal-directed transfusion protocol
via thromboelastography in patients with abdominal trauma: a
retrospective study. World J Emerg Surg 2014;9:28.
34. Stensballe J, Ostrowski SR, Johansson PI. Viscoelastic guid-
ance of resuscitation. Curr Opin Anaesthesiol 2014;27:212-8.
35. Spahn D, Bouillon B, Cerny V, et al. Management of bleeding
and coagulopathy following major trauma: an updated
European guideline. Crit Care 2013;17:R76.
36. Nardi G, Agostini V, Rondinelli B, et al. Trauma-induced coag-
ulopathy: impact of the early coagulation support protocol on
blood product consumption, mortality and costs. Crit Care
2015;19:83.
37. Wang H, Robinson RD, Phillips JL, et al. Traumatic abdominal
solid organ injury patients might benefit from thromboelastog-
raphy-guided blood component therapy. J Clin Med Res
2017;9:433-8.
38. Meyer DE, Reynolds JW, Hobbs R, et al. the incidence of
transfusion-related acute lung injury at a large, urban tertiary
medical center: a decade’s experience. Anesth Analg
2018;127:444-9.
39. Hartert H. Blutherinnungsstudien nit der thromboelastogra-
phie, einem neuen untersuchungsverfarhren. Klinische
Wochenschrift 1948;26:577-83.
40. Hardaway R, Bredenberg C. Monitoring hematology laborato-
ry values. Care of Wounded in Vietnam. Manhatten, Kansas;
1988. pp 139-220.
41. Raza I, Davenport R, Rourke C, et al. The incidence and mag-
nitude of fibrinolytic activation in trauma patients. J Thromb
Haemost 2013;11:307-14.
42. Schochl H, Voelckel W, Maegele M, et al. Trauma-associated
hyperfibrinolysis. Hämostaseologie 2012;32:22-7.
43. Ruzicka J, Stengl M, Bolek L, et al. Hypothermic anticoagula-
tion: testing individual responses to graded severe hypothermia
with thromboelastography. Blood Coagul Fibrinolysis
2012;23:285-9.
44. Jeppesen AN, Kirkegaard H, Ilkjær S, et al. Influence of tem-
perature on thromboelastometry and platelet aggregation in
cardiac arrest patients undergoing targeted temperature man-
agement. Crit Care 2016;20:118.
45. Bolliger D, Seeberger M, Tanaka K. Principles and practice of
thromboelastography in clinical coagulation management and
transfusion practice. Transfus Med Rev 2012;26:1-13.
46. Spiezia L, Radu C, Marchioro P, et al. Peculiar whole blood
rotation thromboelastometry (Rotem) profile in 40 sideropenic
anaemia patients. Thromb Haemost 2008;100:1106-10.
                                                                                                                             Review
No
n-c
om
me
rci
al 
us
e o
nly
